After a challenging period, UnitedHealth Group is showing signs of renewed investor confidence. The healthcare giant’s stock gained approximately 2% on Tuesday, closing at $348.97. This upward movement is being fueled by a combination of strategic corporate action and increasingly positive sentiment from financial analysts.
Analyst Upgrades Reflect Growing Confidence
Market experts on Wall Street are turning more bullish on UnitedHealth’s prospects. Bernstein analyst Lance Wilkes has reiterated his “Outperform” rating while raising his price target from $440 to $444 per share. He identifies the company as his top selection for the year, projecting revenue growth of 12% for 2026—a figure that would significantly outpace its historical average.
This optimistic view is echoed by Barclays, which increased its target price from $386 to $391 and maintains an “Overweight” recommendation. These adjustments suggest that research firms view the current valuation as an attractive entry point, despite the headwinds faced in the previous year.
Strategic Divestment in Focus
A major catalyst for the recent positive momentum appears to be an impending strategic sale. Reports indicate UnitedHealth is nearing an agreement to divest its UK technology unit, Optum UK. Private equity firm TPG is said to be prepared to pay around £1 billion, equivalent to approximately $1.4 billion, for the division.
Should investors sell immediately? Or is it worth buying Unitedhealth?
This potential transaction is interpreted as a strategic refocusing. By exiting non-core international operations, the company would streamline its portfolio and concentrate resources on its core, highly profitable U.S. market. Investors are responding favorably to the prospect, seeing it as a move that could inject fresh capital for reinvestment and signal a drive toward greater operational efficiency.
Rebounding from a Significant Setback
Over the past twelve months, UnitedHealth’s equity has lost about one-third of its value, significantly underperforming the broader healthcare sector. However, the recent price action may signal a potential inflection point. Supporting this notion are reports of investment interest from major institutional players like Berkshire Hathaway, suggesting some see the stock as undervalued at current levels.
The next key technical hurdle for the shares remains a sustained recovery above the $400 mark. Whether the combined effect of portfolio optimization and improved growth forecasts will be sufficient to drive that rally will become clearer in the coming weeks.
Ad
Unitedhealth Stock: Buy or Sell?! New Unitedhealth Analysis from January 8 delivers the answer:
The latest Unitedhealth figures speak for themselves: Urgent action needed for Unitedhealth investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 8.
Unitedhealth: Buy or sell? Read more here...
